[Dendritic cell therapy for malignant glioma]
- PMID: 14571839
[Dendritic cell therapy for malignant glioma]
Abstract
Despite advances in radiation and chemotherapy along with surgical resectioning, the prognosis of patients with malignant glioma is poor. Among the new treatments currently being investigated for malignant glioma, immunotherapy is theoretically very attractive, since it offers the potential for high tumor-specific cytotoxicity. There are increasing reports demonstrating that systemic immunotherapy using dendritic cells is capable of inducing an antiglioma response. Therefore, dendritic cell-based immunotherapy could be a new treatment modality for patients with glioma. Dendritic cell-based immunotherapy strategies appear promising as an approach to successfully induce an antitumor immune response and increase survival in patients with glioma. The development of methods for manipulating dendritic cells for the purpose of vaccination will enhance the clinical usefulness of these cells for biotherapy for malignant glioma.
Similar articles
-
Dendritic cell-based glioma immunotherapy (review).Int J Oncol. 2003 Jul;23(1):5-15. Int J Oncol. 2003. PMID: 12792771 Review.
-
[Peptide vaccination therapy for malignant glioma].Brain Nerve. 2007 Mar;59(3):251-61. Brain Nerve. 2007. PMID: 17370651 Review. Japanese.
-
Novel immunotherapeutic approaches to glioma.Curr Opin Mol Ther. 2006 Feb;8(1):46-51. Curr Opin Mol Ther. 2006. PMID: 16506525 Review.
-
Dendritic cell vaccines.Adv Exp Med Biol. 2012;746:187-200. doi: 10.1007/978-1-4614-3146-6_15. Adv Exp Med Biol. 2012. PMID: 22639169 Review.
-
Cell- and peptide-based immunotherapeutic approaches for glioma.Trends Mol Med. 2008 May;14(5):228-35. doi: 10.1016/j.molmed.2008.03.003. Epub 2008 Apr 9. Trends Mol Med. 2008. PMID: 18403264 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
